Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Charles River Laboratories International Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Charles River Laboratories International şirketinin toplam hissedar öz sermayesi $3.8B ve toplam borcu $2.4B olup, bu da borç-öz sermaye oranını 63.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $7.9B ve $4.2B dir. Charles River Laboratories International 'in FAVÖK'ü $628.1M faiz karşılama oranı 5 dur. Şirketin $179.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
63.2%
Borç/özkaynak oranı
US$2.38b
Borç
| Faiz karşılama oranı | 5x |
| Nakit | US$179.21m |
| Eşitlik | US$3.77b |
| Toplam yükümlülükler | US$4.18b |
| Toplam varlıklar | US$7.95b |
Son finansal sağlık güncellemeleri
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Recent updates
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: CRL 'nin kısa vadeli varlıkları ( $1.5B ) kısa vadeli yükümlülüklerini ( $947.5M ) aşıyor.
Uzun Vadeli Yükümlülükler: CRL 'un kısa vadeli varlıkları ( $1.5B ) uzun vadeli yükümlülüklerini ( $3.2B ) karşılamamaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: CRL 'nin net borç/öz sermaye oranı ( 58.4% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: CRL 'nin borç/öz sermaye oranı son 5 yılda 138.1% seviyesinden 63.2% seviyesine düştü.
Borç Kapsamı: CRL 'nin borcu işletme nakit akışı ( 31.5% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: CRL 'in borcuna ilişkin faiz ödemeleri EBIT ( 5 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.